Research programme: otitis media therapeutics - Novus Therapeutics

Drug Profile

Research programme: otitis media therapeutics - Novus Therapeutics

Alternative Names: OP 0201; OP-02; OP-02 Surfactant

Latest Information Update: 12 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator otodyne
  • Developer Novus Therapeutics; Otodyne
  • Class Palmitates; Phospholipids; Surfactants
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Otitis media

Most Recent Events

  • 10 May 2017 Tokai Pharmaceuticals has merged with Otic Pharma and subsequently changed its name to Novus Therapeutics
  • 30 Dec 2016 Preclinical trials in Otitis media in USA (unspecified route) (Otic Pharma pipeline, December 2016)
  • 22 Dec 2016 Otic Pharma plans a phase II trial for Otitis media (In children) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top